GlassScriptPhysician profile
Debra E Swoverland
NPI 1730500562
$13,782.74
in general payments reported to CMS, 2019-2025
47 companies · $2,890 in 2025
The $2,890 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,300 · 2022: $2,679 · 2023: $2,455 · 2024: $3,458 · 2025: $2,890.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,797 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,796.89 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,726.69 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,376.27 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,156.97 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $927.55 | 2021-2025 | Rybelsus, Wegovy, Ozempic |
| Lilly USA, LLC | $875.06 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Amgen INC. | $718.07 | 2021-2025 | Repatha, Evenity, Prolia |
| Astellas Pharma US INC | $518.30 | 2021-2025 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $506.72 | 2021-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Pfizer INC. | $502.66 | 2021-2025 | |
| Axsome Therapeutics, INC. | $386.41 | 2022-2025 | Auvelity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $385.67 | 2021-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $345.41 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $337.25 | 2021-2025 | Rexulti |
| Lundbeck LLC | $319.66 | 2021-2025 | Rexulti, Vyepti |
| Dexcom, INC. | $298.99 | 2021-2024 | Dexcom G6 Transmitter |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $296.11 | 2021-2024 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $261.72 | 2021-2025 | Trintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $240.50 | 2025 | Caplyta |
| Alkermes, INC. | $214.85 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Exact Sciences Corporation | $184.29 | 2023-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $184.01 | 2021-2023 | Belsomra, Lagevrio |
| Sunovion Pharmaceuticals INC. | $179.73 | 2021-2022 | |
| Corium, LLC | $165.96 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $142.72 | 2021-2025 | Spravato |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.75 | 2023-2024 | Xifaxan |
| Supernus Pharmaceuticals, INC. | $117.22 | 2021-2023 | Qelbree |
| Neurocrine Biosciences, INC. | $116.22 | 2021-2025 | Ingrezza |
| Eisai INC. | $114.39 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $111.84 | 2021-2025 | Eliquis, Camzyos |
| Aimmune Therapeutics, INC. | $110.80 | 2024-2025 | Zenpep |
| Jazz Pharmaceuticals INC. | $107.75 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $103.17 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $78.65 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $73.57 | 2025 | Fanapt |
| Indivior INC. | $63.28 | 2024 | Sublocade |
| Sumitomo Pharma America, INC. | $59.93 | 2024 | Gemtesa |
| Antares Pharma, INC. | $57.81 | 2021-2024 | Xyosted |
| Kowa Pharmaceuticals America, INC. | $54.18 | 2021-2025 | Zoryve |
| Medtronic, INC. | $50.35 | 2022-2025 | Minimed 780g |
| Avanir Pharmaceuticals, INC. | $41.61 | 2022 | |
| Boston Scientific Corporation | $33.01 | 2023-2024 | |
| Corcept Therapeutics | $23.24 | 2025 | Korlym |
| Viatris Specialty LLC | $22.82 | 2025 | Yupelri |
| Radius Health, INC. | $20.21 | 2024 | Tymlos |
| Esperion Therapeutics, INC. | $18.34 | 2021 | |
| Xeris Pharmaceuticals, INC. | $16.12 | 2024 | Gvoke Hypopen |
| Philips North America LLC | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Swoverland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.